Compare Quantumscape Corp (QS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Quantumscape Corp trades at $3.89 (market cap $2.55B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.9× Quantumscape Corp's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QS | SYRE | |
|---|---|---|
Market Cap | $2.55B | $7.35B |
Volume | 12,145,789 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $108.92 |
52-Week Low | $3.93 | $22.18 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $1.76B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.12, down 3.51% with a bearish technical outlook despite oversold RSI readings. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative ROE/ROA. Recent news highlights commercialization delays and insider selling, while analyst consensus shows 73% hold ratings with a $10.35 price target representing 151% upside potential.
QS presents high-risk speculation with substantial upside if solid-state battery technology succeeds, but faces execution risks and cash burn. The stock trades near 52-week lows with negative cash flow trends, requiring careful risk management given the 5+ year commercialization timeline and competitive threats in EV battery development.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
